No Data
No Data
RemeGen Gets China Marketing Nod for Rheumatoid Arthritis Drug Combo
RemeGen's Telitacicept Wins NMPA Approval
Remegen (09995.HK): Taitaizipu (commodity name: Tai'ai) has been fully approved by the National Medical Products Administration for the treatment of rheumatoid arthritis patients.
On July 22, GeLongHui reported that Remegen (09995.HK) announced that Taltz (generic name: ixekizumab) has officially obtained the complete approval for marketing in China from the National Medical Products Administration (NMPA) for treating adult patients with moderate to severe active rheumatoid arthritis (RA) who have poor response to methotrexate. The approval of Taltz in this indication is based on a random, double-blind, placebo-controlled and multicenter phase III clinical trial that evaluated the use of Taltz based on methotrexate in 479 patients with RA. The trial aimed to evaluate the efficacy and safety of Taltz combination therapy.
Express News | RemeGen - Full Approval of Telitacicept by Nmpa
The actual controller of Remegen has accumulated a shareholding of 0.18 million shares in the company, involving 5.109 million yuan.
Remegen (09995) announced the progress of the controlling shareholder's shareholding in the company. From July 9, 2024 to July 16, 2024, the company's controlling shareholders Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, Wei Jianliang, through their controlled enterprise Yantai Rongchang Holdings Group Co., Ltd., increased their holding of the company's shares by 0.18 million shares, accounting for 0.0331% of the total share capital of the company, with a total amount of RMB 5.109 million (excluding transaction fees) through the centralized bidding method on the Shanghai Stock Exchange system.
Remegen received a cumulative shareholding of 0.18 million shares from its controlling shareholder.
Remegen (688331.SH) announced that from July 9, 2024 to July 16, 2024, the company's actual controller Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, and Wei Jianliang will increase their shareholding in the company by 0.18 million shares through their controlled enterprise Yantai Rongchang Holding Group Co., Ltd. via the Shanghai Stock Exchange's centralized bidding system.
No Data